Search | Clinical Trials Finder

Conditions: Opioid-use Disorder, Suicidal Ideation
Interventions: Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film, Morphine Sulfate 30 mg; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more

Conditions: Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions: Anamorelin Hydrochloride, Placebo Oral Tablet; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more

Conditions: Chronic Low Back Pain
Interventions: Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more

Conditions: Agitation, Schizophrenia
Interventions: Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more

Conditions: Schizophrenia
Interventions: Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 76 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 8 more

Conditions: HIV-1
Interventions: D/C/F/TAF FDC placebo; Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more

Conditions: Drug Interaction, Analgesics, Opioid Use Disorder
Interventions: Lemborexant, Placebo, Buprenorphine-naloxone; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Peripheral Neuropathy
Interventions: Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System; Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Salt Lake City, Utah

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Tucson, Arizona • Roseville, California • Upland, California + 21 more

Conditions: Alzheimer's Disease
Interventions: ELND005, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Conditions: Myasthenia Gravis
Interventions: Tolebrutininb, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Boca Raton, Florida • Tampa, Florida + 2 more

Conditions: Chronic Kidney Failure
Interventions: Fermagate, Placebo; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina

Conditions: Foot Ulcer, Diabetic
Interventions: DERMASEAL, Plasma Film, Standard of Care; Combination Product · Biological · Other
Lead sponsor: Vitruvian Medical Devices, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Fresno, California • South Miami, Florida • Boardman, Ohio + 1 more

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Macitentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Opioid Withdrawal
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Lakes, Florida • Marlton, New Jersey • New York, New York

Conditions: Chronic Pain, Nociceptive Pain
Interventions: CNTX-6970, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dry Eye Disease
Interventions: OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Vance Thompson Vision ND; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: West Fargo, North Dakota

Conditions: HIV-associated Lipodystrophy Syndrome
Interventions: GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: KB15A Vaginal Film, Placebo Vaginal Film; Drug
Lead sponsor: ZabBio Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Palmoplantar Pustulosis
Interventions: RIST4721, Placebo; Drug
Lead sponsor: Aristea Therapeutics, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Bryant, Arkansas • San Diego, California + 16 more

Conditions: HIV, Herpes Simplex Infections
Interventions: MB66, Placebo Film; Drug
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Atrasentan in Patients With IgA Nephropathy

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

Phase 1 Study of Intravaginal KB15A

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV